bleomycine sanofi 15 000 iu inj. sol. (pwdr.) i.perit./i.pleur./s.c./i.arter./i.v./i.tumor./i.m. vial
sanofi belgium sa-nv - bleomycin sulfate 15 mg - powder for solution for injection - 15000 iu - bleomycin sulfate 15 mg - bleomycin
bleomycin- bleomycin sulfate powder, for solution
meitheal pharmaceuticals inc. - bleomycin sulfate (unii: 7dp3ntv15t) (bleomycin - unii:40s1vhn69b) - bleomycin for injection, usp should be considered a palliative treatment. it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: squamous cell carcinoma: head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. the response to bleomycin for injection, usp is poorer in patients with previously irradiated head and neck cancer. lymphomas: hodgkin's disease, non-hodgkin's lymphoma. testicular carcinoma: embryonal cell, choriocarcinoma, and teratocarcinoma. bleomycin for injection, usp has also been shown to be useful in the management of: malignant pleural effusion: bleomycin for injection, usp is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. bleomycin for injection is contraindicated in patients who ha
bleomycin powder, for solution
northstar rx llc - bleomycin sulfate (unii: 7dp3ntv15t) (bleomycin - unii:40s1vhn69b) - bleomycin for injection, usp should be considered a palliative treatment. it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: squamous cell carcinoma: head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. the response to bleomycin for injection, usp is poorer in patients with previously irradiated head and neck cancer. lymphomas: hodgkin's disease, non-hodgkin's lymphoma. testicular carcinoma: embryonal cell, choriocarcinoma, and teratocarcinoma. bleomycin for injection, usp has also been shown to be useful in the management of: malignant pleural effusion: bleomycin for injection, usp is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. bleomycin for injection is contraindicated in patients who ha
bleomycin injection
cipla usa inc. - bleomycin sulfate (unii: 7dp3ntv15t) (bleomycin - unii:40s1vhn69b) - bleomycin for injection should be considered a palliative treatment. it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: squamous cell carcinoma: head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. the response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. lymphomas: hodgkin's disease, non-hodgkin's lymphoma. testicular carcinoma: embryonal cell, choriocarcinoma, and teratocarcinoma. bleomycin for injection has also been shown to be useful in the management of: malignant pleural effusion: bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. bleomycin for injection is contraindicated in patients who have demonstrated
bleomycin for injection powder for solution
fresenius kabi canada ltd - bleomycin (bleomycin sulfate) - powder for solution - 15unit - bleomycin (bleomycin sulfate) 15unit - antineoplastic agents
bleomycin for injection usp powder for solution
pfizer canada ulc - bleomycin (bleomycin sulfate) - powder for solution - 15unit - bleomycin (bleomycin sulfate) 15unit - antineoplastic agents
cipla bleomycin 15k bleomycin sulfate 15000 iu powder for injection vial
cipla australia pty ltd - bleomycin sulfate, quantity: 15000 iu - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid - palliation and treatment adjuvant to surgery and radiation therapy of the following neoplasms: squamous cell carcinoma of the skin, head and neck, and oesophagus (primary indication). squamous cell carcinoma of the larynx, penis and uterine cervix. squamous cell carcinoma of the bronchus (response infrequent). choriocarcinoma and embryonal cell carcinoma of the testis. advanced hodgkin's disease and other lymphomas. mycosis fungoides note. use of bleomycin after radiation therapy is less successful than use before radiation therapy. bleomycin is bone marrow sparing and may be used when other cytotoxic agents are contraindicated.
bleo 15k bleomycin sulfate 15000 iu powder for injection vial
juno pharmaceuticals pty ltd - bleomycin sulfate, quantity: 15000 iu - injection, powder for - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - palliation and treatment adjuvant to surgery and radiation therapy of the following neoplasms: = squamous cell carcinoma of the skin, head and neck, and oesophagus (primary indication). = squamous cell carcinoma of the larynx, penis and uterine cervix. = squamous cell carcinoma of the bronchus (response infrequent). = choriocarcinoma and embryonal cell carcinoma of the testis. = advanced hodgkin's disease and other lymphomas. = mycosis fungoides.,note. use of bleomycin after radiation therapy is less successful than use before radiation therapy. bleomycin is bone marrow sparing and may be used when other cytotoxic agents are contraindicated.
bambermycin 8%
international animal health products pty ltd - bambermycin - unknown - bambermycin ab active 0.0 - active constituent
bambermycin 4%
international animal health products pty ltd - bambermycin - unknown - bambermycin ab active 0.0 - active constituent